Evaluation of the Effect of Selenium Consumption on the Regulatory Cells of the Immune System in Patients with non-Hodgkin Lymphoma

Evaluation of the Effect of Selenium Consumption on the Frequency of Regulatory T cells (Tregs) in Patients with non-Hodgkin Lymphoma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200128046292N1

Enrollment

Registered

2020-03-02

Start date

2018-04-21

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-Hodgkin's lymphoma patients with DLBCL subtype. Diffuse large B-cell lymphoma

Interventions

Intervention 1: Intervention group: Non-Hodgkin's lymphoma patients with DLBCL subtype who consume 200 mcg of selenium orally every day for 3 months. Intervention 2: Control group: Non-Hodgkin's lymph

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with non-Hodgkin lymphoma with diffuse large B-cell lymphoma (DLBCL) subtype Patient at remission phase

Exclusion criteria

Exclusion criteria: Patients with Non-Hodgkin Lymphoma with other Disease Subtype than Diffuse Large B-Cell Lymphoma (DLBCL) Patient Being in Active Phase of the Disease

Design outcomes

Primary

Measure	Time frame
Changes in the frequency of Treg lymphocytes after 3 months of selenium consumption. Timepoint: At the beginning of the study and 3 months later. Method of measurement: Flow cytometry test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehdi Dehghani

Shiraz University of Medical Sciences

dehghanim@sums.ac.ir+98 71 3612 5131

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026